Business Description
DBV Technologies SA
ISIN : US23306J3095
Share Class Description:
DBVT: ADRTotal Employee Number:
161Compare
Compare
Traded in other countries / regions
DBV.FranceDBVT.USADBV.Germany0QAJ.UK IPO Date
2014-10-22Description
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 37.58 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 5.8 | |||||
3-Year EPS without NRI Growth Rate | 8.5 | |||||
3-Year FCF Growth Rate | -2.7 | |||||
3-Year Book Growth Rate | -32.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 422.17 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 59.19 | |||||
9-Day RSI | 53.92 | |||||
14-Day RSI | 49.76 | |||||
3-1 Month Momentum % | -25.62 | |||||
6-1 Month Momentum % | -5.88 | |||||
12-1 Month Momentum % | 50.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.76 | |||||
Quick Ratio | 4.76 | |||||
Cash Ratio | 4.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -35.8 | |||||
Shareholder Yield % | -36.81 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -161.28 | |||||
ROA % | -103.57 | |||||
ROIC % | -528.4 | |||||
3-Year ROIIC % | 773.09 | |||||
ROC (Joel Greenblatt) % | -1056.75 | |||||
ROCE % | -151.23 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 22.57 | |||||
PB Ratio | 4.53 | |||||
Price-to-Tangible-Book | 4.53 | |||||
EV-to-EBIT | -4.2 | |||||
EV-to-EBITDA | -4.41 | |||||
EV-to-Forward-Revenue | 193.07 | |||||
EV-to-FCF | -4.68 | |||||
| Price-to-Net-Current-Asset-Value | 5.03 | |||||
| Price-to-Net-Cash | 5.53 | |||||
Earnings Yield (Greenblatt) % | -23.81 | |||||
FCF Yield % | -16.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:DBVT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
DBV Technologies SA Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -4.45 | ||
| Beta | -1.0467 | ||
| 3-Year Sharpe Ratio | 0.21 | ||
| 3-Year Sortino Ratio | 0.38 | ||
| Volatility % | 70.83 | ||
| 14-Day RSI | 49.76 | ||
| 14-Day ATR ($) | 1.074985 | ||
| 20-Day SMA ($) | 16.29175 | ||
| 12-1 Month Momentum % | 50.98 | ||
| 52-Week Range ($) | 8.51 - 26.185 | ||
| Shares Outstanding (Mil) | 59.19 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
DBV Technologies SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
DBV Technologies SA Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-10-28 | In 111 days | ||
| Second quarter earnings results for 2026 | 2026-07-29 | In 20 days | ||
| DBV Update Conference Call | 2026-06-29 17:00 | 16.01 (+2.10%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 09:20 | 16.00 (-4.48%) | ||
| General meeting for 2026 | 2026-06-03 10:00 | 18.23 (+0.66%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 09:00 | 18.75 (-3.00%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 20.30 (-3.01%) | ||
| Annual report for 2025 | 2026-03-26 | 20.27 (+0.30%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 20.27 (+0.30%) | ||
| Citizens Life Sciences Conference | 2026-03-10 13:40 | 22.90 (+3.20%) |
Show
Entries
DBV Technologies SA Frequently Asked Questions
What is DBV Technologies SA(DBVT)'s stock price today?
The current price of DBVT is $16.08. The 52 week high of DBVT is $26.19 and 52 week low is $8.51.
When is next earnings date of DBV Technologies SA(DBVT)?
The next earnings date of DBV Technologies SA(DBVT) is 2026-07-29 Est..
Does DBV Technologies SA(DBVT) pay dividends? If so, how much?
DBV Technologies SA(DBVT) does not pay dividend.
Guru Commentaries on NAS:DBVT
No articles.
Press Release
Articles on DBV Technologies SA
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers